There are a lot of companies claiming they can fix pain without opioids.

It’s basically a genre at this point.

But Sparian Biosciences just got something most of them don’t have: $15 million from the NIH to prove it.

The company kicked off a Phase 1 trial of SBS-147, an oral small molecule that targets something called the arylepoxamide receptor, or AEAr.

If you haven’t heard of it, you’re not alone.

This isn’t a warmed-over opioid receptor story or another CGRP play. It’s a genuinely different target, and the NIH’s HEAL Initiative decided it was worth a big check.

The trial is your standard Phase 1 setup: single and multiple ascending doses in healthy adults, looking at safety, tolerability, and PK.

Nothing flashy.

But the preclinical data is what got the grant. SBS-147 showed pain relief across both nociceptive and neuropathic models, and critically, no respiratory depression and no abuse potential.

That’s the whole ballgame in non-opioid pain.

SBS-147 is actually a next-gen follow-on to Sparian’s earlier compound, SBS-1000, which is a parenteral AEAr agonist.

The oral version is the commercial play, obviously. You can’t send patients home with an IV bag for chronic pain.

The non-opioid pain space is getting crowded with aspirational programs. Algia Pharma has AlgiaPak heading toward Phase 2 with FDA support. ZYUS Life Sciences raised C$15M for Trichomylin softgels.

But most of these are working known mechanisms.

Sparian is swinging at a target that barely has a Wikipedia page, and the federal government is co-signing it. That’s either visionary or very expensive optimism.

The Phase 1 data will tell us which.

The HEAL grant also covers Phase 2 progression, which means Sparian has runway to get through proof-of-concept without raising a dime of private capital.

For a New York-based biotech with a novel target and zero disclosed VC backing, that’s a pretty good deal.